<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234194</url>
  </required_header>
  <id_info>
    <org_study_id>CVI_2010</org_study_id>
    <nct_id>NCT01234194</nct_id>
  </id_info>
  <brief_title>Composite Variability Index and Propofol Remifentanil Anesthesia</brief_title>
  <official_title>Changes in the Composite Variability Index in Response to Different Remifentanil Concentrations and Standardized Painful Stimuli.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if the new Composite Variability Index (CVI) is
      capable of detecting changing effect compartment concentrations of remifentanil. In addition,
      it is planed to detect if the change in CVI in response to a standardized painful stimulus is
      dose-dependent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On the day of surgery, patients receive anesthesia by propofol infusion. As soon as the
      patient is unresponsive und unconscious (BIS 40-60) and a steady state is achieved, a
      standardized painful stimulus is applied by electrical stimulation of the ulnar nerve
      (tetanic stimulation [70 mA], 30 seconds, 50 Hz) in group 1. Thereafter remifentanil is
      infused to an effect compartment concentration target of 1 ng/ml. The standardized stimulus
      is applied again as the remifentanil target is reached. This procedure is repeated with
      remifentanil targets of 2 ng/ml and 3ng/ml. In group 2 remifentanil is targeted to effect
      compartment concentrations of 3 ng/ml followed by 2,1, and 0 ng/ml.

      After measuring the effect of the last painful stimulus the patient is intubated for surgery.
      Throughout the study the Composite Variability Index and standard monitoring is recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction Probability of CVI versus remifentanil effect compartment concentration and versus movement after painful stimulus</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Measure of Nociception</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rising remifentanil concentrations</intervention_name>
    <description>remifentanil effect-compartment concentrations 0,1,2,3 ng/ml</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>falling remifentanil concentrations</intervention_name>
    <description>remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing surgical procedure in general anesthesia

        Exclusion Criteria:

          -  Pregnancy, drug abuse, cardiac arrhythmia, obesity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard K Ellerkmann, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bonn</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <last_update_submitted>November 3, 2010</last_update_submitted>
  <last_update_submitted_qc>November 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Richard Klaus Ellerkmann / M.D.</name_title>
    <organization>University of Bonn</organization>
  </responsible_party>
  <keyword>Composite Variability Index</keyword>
  <keyword>Bispectral Index</keyword>
  <keyword>Electromyography</keyword>
  <keyword>Nociception</keyword>
  <keyword>Pain</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

